ASCO Daily News

134 Episoder

1. What the FDA CAR T-Cell Therapy Investigation Means for Oncologists

   Publisert: 7.12.2023
2. Managing the Complexities of Oncology Practice in 2024

   Publisert: 7.12.2023
3. Solutions and Key Research to Advance High-Quality Cancer Care

   Publisert: 9.11.2023
4. How to Implement Universal Germline Testing for CRC

   Publisert: 2.11.2023
5. Changing the Gut Microbiome to Improve the Efficacy of Immunotherapy

   Publisert: 12.10.2023
6. Navigating the Complexities of Next-Generation Endocrine Therapy in HR+ Breast Cancer

   Publisert: 28.9.2023
7. ASCO Breakthrough: Scientific Innovations and Emerging Technologies in Cancer Care

   Publisert: 17.8.2023
8. How Oncologists Are Confronting the Cancer Drug Shortage

   Publisert: 10.8.2023
9. AI Will Allow Doctors to Reclaim Time With Patients

   Publisert: 3.8.2023
10. Managing the Side Effects of Endocrine Therapy for Breast Cancer

    Publisert: 27.7.2023
11. The Emergence of Triplet Therapies in ccRCC in the Frontline Setting

    Publisert: 13.7.2023
12. Novel Therapies in GI Oncology at ASCO23

    Publisert: 28.6.2023
13. THOR, CONTACT-03, and Other Advances in GU Cancers at ASCO23

    Publisert: 27.6.2023
14. Spotlight on Immunotherapy at ASCO23

    Publisert: 26.6.2023
15. Highlights in Hematologic Malignancies at ASCO23

    Publisert: 23.6.2023
16. ADAURA, KEYNOTE-671, and Other Key Advances in Lung Cancer at ASCO23

    Publisert: 22.6.2023
17. SONIA, NATALEE, and Other Advances in Breast Cancer at ASCO23

    Publisert: 21.6.2023
18. Addressing the Impact of Prior Authorization on Access to Cancer Treatment

    Publisert: 8.6.2023
19. ASCO23: RELATIVITY-047, CheckMate-038, and Other Advances in Immunotherapy

    Publisert: 25.5.2023
20. ASCO23: COMMANDS, CAPTIVATE, and Key Studies in Hematologic Malignancies

    Publisert: 25.5.2023